# Answer Generation Prompt: SZ-A / Mulberry Mechanisms in Atherosclerosis

You are a biomedical research assistant. Answer the user's question in a concise evidence-grounded Markdown table.

## User Question

Based on the provided results, explain the potential protective effects of the drug against atherosclerosis. Then, based on the LLM explanation, explain why these three mechanisms were selected instead of other mechanisms: (1) TMAO-FMO3 and liver lipid or bile acid metabolism; (2) inflammation and oxidative stress; and (3) endothelial uptake of oxLDL.

You must seriously use PubMed/PMC and peer-reviewed sources. Do not rely on unsourced claims. Do not use illicit full-text sources; use PubMed, PMC, publisher abstracts, and legitimate open-access pages.

## Output Requirements

- Output a Markdown table only.
- Each cell should be brief and within 100 words.
- Include a confidence score within [1, 5] in the last column; 5 means the highest confidence.
- The table must use exactly these columns:

| Core Mechanism | SZ-A Results in PDF (Atherosclerosis Model) | Known Effects of Mulberry Twig Total Alkaloids (DNJ, DAB, etc.) | Known Effects of Mulberry Extract (General) | Known Effects of Mulberry Polysaccharides | Rationale for Mechanism Selection | Score & Justification |
|---|---|---|---|---|---|---|

- Use exactly these three rows:
  1. TMAO-FMO3 & Liver Metabolism
  2. Inflammation & Oxidative Stress
  3. Endothelial Uptake of oxLDL

## Evidence to Use

- Provided PDF: SZ-A reduces plaque/lesion area; improves AST/ALT; lowers TMA-producing bacteria/TMA-lyase and inhibits hepatic FMO3; regulates cholesterol/bile-acid related genes such as Abcg1 and bile acid synthesis/transport; lowers CRP, TNF-alpha, CCL-4, CXCL9, oxLDL/LDL; improves SOD; reduces ROS/MDA/IL-6/TNF-alpha/MCP-1 in macrophage assays; decreases endothelial oxLDL uptake and BODIPY lipid signals. Serum TMAO was not detected, so avoid overclaiming systemic TMAO.
- SZ-A atherosclerosis: Peng et al., Phytomedicine 2024, DOI 10.1016/j.phymed.2024.155526. SZ-A mitigated AS by regulating macrophage M1/M2 polarization and CXCL10-mediated endothelial/macrophage inflammatory amplification.
- SZ-A cholesterol/gut-liver metabolism: Li et al., ACS Omega 2025, PMID 40821600, PMCID PMC12355231. SZ-A lowered TC/LDL-C, changed gut microbiota, promoted bile acid excretion, and regulated hepatic FXR/CYP7A1/SHP pathways.
- SZ-A inflammation/metabolism: Liu et al., Front Pharmacol 2021, PMID 33935735, PMCID PMC8082153. SZ-A improved glucose/lipid metabolism, gut microbiota, ileal barrier injury, inflammatory macrophage infiltration, endotoxin, cytokines, and chemokines.
- Mulberry extract and LDL/endothelium: Doi et al., Biol Pharm Bull 2000, PMID 10993206; Chan et al., Food Funct 2013, PMID 23428158; Chao et al., Evid Based Complement Alternat Med 2013, PMID 24371453; Nutrients 2019 endothelial dysfunction study, PMCID PMC6566444.
- Mulberry polysaccharides: Dai et al., Int J Biol Macromol 2024, PMID 39490871, gut microbiota-bile acids pathway; MLP obesity/HFD study, PMID 34951619.

## Reasoning Guidance

Choose the three mechanisms because they meet all three filters:

1. They are directly supported by the provided SZ-A atherosclerosis PDF.
2. They are causal or proximal to atherosclerosis biology: gut-liver TMAO/cholesterol/bile acids, inflammatory/oxidative plaque amplification, and endothelial oxLDL uptake.
3. They are supported by known SZ-A/mulberry literature.

Explain why not other mechanisms: glucose lowering, general microbiome shifts, intestinal barrier/Paneth cells, VSMC proliferation, or broad lipid lowering are useful background mechanisms but are either less directly shown in this PDF, less vascular-local, or more upstream/indirect for the presented AS model.
